Atom Investors LP Has $8.12 Million Stock Position in Encompass Health Corporation $EHC

Atom Investors LP lifted its stake in shares of Encompass Health Corporation (NYSE:EHC) by 110.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 76,487 shares of the company’s stock after buying an additional 40,080 shares during the period. Encompass Health makes up 0.6% of Atom Investors LP’s investment portfolio, making the stock its 28th biggest position. Atom Investors LP’s holdings in Encompass Health were worth $8,118,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. EP Wealth Advisors LLC grew its holdings in shares of Encompass Health by 2.4% during the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company’s stock worth $453,000 after purchasing an additional 88 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Encompass Health by 14.7% during the 3rd quarter. Allworth Financial LP now owns 701 shares of the company’s stock worth $89,000 after purchasing an additional 90 shares in the last quarter. Leuthold Group LLC grew its holdings in shares of Encompass Health by 0.3% during the 4th quarter. Leuthold Group LLC now owns 31,168 shares of the company’s stock worth $3,308,000 after purchasing an additional 104 shares in the last quarter. Covestor Ltd lifted its position in shares of Encompass Health by 24.4% during the 4th quarter. Covestor Ltd now owns 540 shares of the company’s stock worth $57,000 after buying an additional 106 shares during the last quarter. Finally, Benjamin Edwards Inc. lifted its position in shares of Encompass Health by 1.4% during the 4th quarter. Benjamin Edwards Inc. now owns 8,008 shares of the company’s stock worth $850,000 after buying an additional 112 shares during the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Price Performance

Encompass Health stock opened at $99.92 on Wednesday. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $9.91 billion, a PE ratio of 16.68, a P/E/G ratio of 2.17 and a beta of 0.72. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99. The stock has a 50-day moving average price of $104.40 and a two-hundred day moving average price of $104.36.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, April 30th. The company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.51 by $0.09. The firm had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the company earned $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Analysts expect that Encompass Health Corporation will post 5.97 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be given a $0.19 dividend. The ex-dividend date is Wednesday, July 1st. This represents a $0.76 annualized dividend and a yield of 0.8%. Encompass Health’s dividend payout ratio (DPR) is currently 12.69%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Barclays dropped their price objective on Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings restated a “buy (b-)” rating on shares of Encompass Health in a research report on Monday, June 8th. TD Cowen assumed coverage on Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 price objective for the company. Finally, Leerink Partners set a $152.00 price objective on Encompass Health in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Encompass Health currently has an average rating of “Buy” and an average target price of $143.86.

Insider Buying and Selling

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the transaction, the executive vice president directly owned 24,755 shares in the company, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.80% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.